RB-N phosphorylation promotes BRD4-mediated GPCR signaling hyperactivation and BET inhibitor resistance
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA683660 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR13221437_1.fastq.gz | Fastqsanger.gz | |||
| SRR13221437_2.fastq.gz | Fastqsanger.gz | |||
| SRR13221438_1.fastq.gz | Fastqsanger.gz | |||
| SRR13221438_2.fastq.gz | Fastqsanger.gz | |||
| SRR13221439_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:The combination of CREB inhibitor and JQ1 could overcome the resistance to BET inhibitors in RB loss prostate cancer. Our study firstly showed that ADRB2-CREB pathway was activated after RB loss and considered as the potential target for the prostate cancer therapy
2021-12-31 | GSE162897 | GEO
Project description:RB-N phosphorylation promotes BRD4-mediated CREB signaling hyperactivation and BET inhibitor resistance
| PRJNA790814 | ENA
Project description:The combination of CREB inhibitor and JQ1 could overcome the resistance to BET inhibitors in RB loss prostate cancer. Our study firstly showed that GNB1L-CREB pathway was activated after RB loss and considered as the potential target for the prostate cancer therapy
2022-08-30 | GSE191263 | GEO
Project description:Liver cancer claims over 800,000 human deaths each year. Liver cancer is notoriously refractory to conventional therapeutics. Further insight into the etiology carries promise for innovative diagnostics and therapeutics. Tumor progression is governed by interplay between tumor promoting genes and suppressor genes. BRD4, an acetyl-lysine binding protein, plays a critical role in development and human diseases. In many cancer types, BRD4 is overexpressed and promotes activation of a pro-tumor gene network. But the underlying mechanism for BRD4 overexpression remains elusive. As BRD4 has risen as a promising therapeutic target, to understand the mechanism regulating BRD4 protein level will shed insight into BRD4-targeting therapeutics. In this study, we find BRD4 protein level in liver cancer is significantly regulated by P53, the most frequently dysregulated tumor suppressor. We identify a strong negative correlation between protein levels of P53 and BRD4 in liver cancer. We then show P53 promotes BRD4 protein degradation. Mechanistically, P53 represses the transcription of USP1, a deubiquitinase, through P21-RB. We show USP1 is a deubiquitinase of BRD4, which increases its stability. We show the pro-tumor role of USP1 is partially mediated by BRD4 and the USP1-BRD4 axis upholds expression of a group of cancer-related genes. In summary, we identify a functional P53-P21-RB-USP1-BRD4 axis in liver cancer.
2024-01-26 | GSE243936 | GEO
Project description:BET bromodomain inhibitors block binding of bromodomain 1 and 2 (BD1, BD2) of BET family proteins to chromatin, and have demonstrated clinical on-target activity in NUT carcinoma (NC), a BRD-NUT fusion oncoprotein-driven cancer. However, toxicity due to inhibition of BD1 has limited the effectiveness of these compounds. A second generation, highly BD2-selective BET inhibitor, DC-9476, was developed to treat non-neoplastic conditions while minimizing toxicity. We find that, in contrast to non-NC cells, NC cells are uniquely sensitive to inhibition by DC-9476 and other BD2-selective inhibitors, which phenocopy the pro-differentiation, growth-arresting effects of non-selective (pan-BD) BET bromodomain inhibition or BRD4-NUT knockdown. We performed total RNA bulk RNAseq to determine what transcriptional changes occur in response to treatment with DC-9476 over a time course (18h, 36h, 48h) in 10-15, 10326 NC cells, and HCC-95 squamous lung non-NC cells. While there were not differentially expressed gene in HCC-95 cells, both 10326 and 10-15 cells showed transcriptional changes consistent with squamous/epithlelial differentiation, and downregulation of translation-associated genes. To understand the basis for this differential sensitivity, we performed a CRISPR knockout screen, which identified the BRD4-targeting E3 ligase, SPOP, as the top hit that confers resistance of NC to DC-9476, suggesting that proteasomal degradation of BRD4/BRD4-NUT is a key vulnerability of NC to BD2-selective BET inhibition. Indeed, treatment with diverse BD2-selective BET inhibitors, but not BD1-selective inhibitors, leads to proteasomal degradation of wild type BRD4 and BRD4-NUT, both of which are required for NC growth, in vitro and in vivo. Importantly, knockout of SPOP prevents loss of BRD4 and BRD4-NUT, and nearly completely rescues NC cells from differentiation and growth arrest induced by BD2 inhibition. Moreover, deletion of the canonical SPOP degron in exogenously expressed BRD4-NUT prevents its degradation from BD2 inhibition. To determine what effects BD2i (DC-9476) has on the chromatin occupancy of BRD4/BRD3-NUT, BRD4L, and H3K27ac, we performed CUT&RUN on NC cells, 10-15 and 10326, and non-NC cells, HCC-95. We found that BD2 inhibition also displaces BRD4, BRD4-NUT, and BRD3-NUT from chromatin, suggesting that degradation is coupled to chromatin release. We leveraged this unique vulnerability in pre-clinical NC models and found that BD2-selective inhibitors achieved significantly greater inhibition of growth and prolonged survival than older generation pan-BD BET inhibitors
2026-09-14 | GSE332674 | GEO
Project description:BET bromodomain inhibitors block binding of bromodomain 1 and 2 (BD1, BD2) of BET family proteins to chromatin, and have demonstrated clinical on-target activity in NUT carcinoma (NC), a BRD-NUT fusion oncoprotein-driven cancer. However, toxicity due to inhibition of BD1 has limited the effectiveness of these compounds. A second generation, highly BD2-selective BET inhibitor, DC-9476, was developed to treat non-neoplastic conditions while minimizing toxicity. We find that, in contrast to non-NC cells, NC cells are uniquely sensitive to inhibition by DC-9476 and other BD2-selective inhibitors, which phenocopy the pro-differentiation, growth-arresting effects of non-selective (pan-BD) BET bromodomain inhibition or BRD4-NUT knockdown. We performed total RNA bulk RNAseq to determine what transcriptional changes occur in response to treatment with DC-9476 over a time course (18h, 36h, 48h) in 10-15, 10326 NC cells, and HCC-95 squamous lung non-NC cells. While there were not differentially expressed gene in HCC-95 cells, both 10326 and 10-15 cells showed transcriptional changes consistent with squamous/epithlelial differentiation, and downregulation of translation-associated genes. To understand the basis for this differential sensitivity, we performed a CRISPR knockout screen, which identified the BRD4-targeting E3 ligase, SPOP, as the top hit that confers resistance of NC to DC-9476, suggesting that proteasomal degradation of BRD4/BRD4-NUT is a key vulnerability of NC to BD2-selective BET inhibition. Indeed, treatment with diverse BD2-selective BET inhibitors, but not BD1-selective inhibitors, leads to proteasomal degradation of wild type BRD4 and BRD4-NUT, both of which are required for NC growth, in vitro and in vivo. Importantly, knockout of SPOP prevents loss of BRD4 and BRD4-NUT, and nearly completely rescues NC cells from differentiation and growth arrest induced by BD2 inhibition. Moreover, deletion of the canonical SPOP degron in exogenously expressed BRD4-NUT prevents its degradation from BD2 inhibition. To determine what effects BD2i (DC-9476) has on the chromatin occupancy of BRD4/BRD3-NUT, BRD4L, and H3K27ac, we performed CUT&RUN on NC cells, 10-15 and 10326, and non-NC cells, HCC-95. We found that BD2 inhibition also displaces BRD4, BRD4-NUT, and BRD3-NUT from chromatin, suggesting that degradation is coupled to chromatin release. We leveraged this unique vulnerability in pre-clinical NC models and found that BD2-selective inhibitors achieved significantly greater inhibition of growth and prolonged survival than older generation pan-BD BET inhibitors
2026-09-14 | GSE332774 | GEO
Project description:Data independent acquisition (DIA) mass spectrometry was used to study the selectivity of 2J2V for BET proteins from A549 cells. BET proteins, BRD2, BRD3 and BRD4 were observed to be degraded the most by 2J2V in comparison to MZ1 or DMSO.
2024-10-08 | PXD049407 | Pride
Project description:BRD4 functions as an epigenetic reader and plays a crucial role in regulating transcription and genome stability. Dysregulation of BRD4 is frequently observed in various human cancers. However, the molecular details of BRD4 regulation remain largely unknown. Here, we report that PRMT2- and PRMT4-mediated arginine methylation is pivotal for BRD4-dependent transcription, DNA repair, and tumor growth. Specifically, PRMT2/4 interact with and methylates BRD4 at R179, R181, and R183. This arginine methylation selectively controls a transcriptional program by promoting BRD4 enrichment at the hyper-acetylated chromatin regions. Moreover, BRD4 arginine methylation is induced by DNA damage and thereby promotes its binding to chromatin for DNA repair. Deficiency in BRD4 arginine methylation significantly suppresses tumor growth and sensitizes cells to BET inhibitors and DNA damaging agents. Therefore, our findings reveal an arginine methylation-dependent regulatory mechanism of BRD4 function and highlight targeting PRMT2/4 for better anti-tumor effect of BET inhibitors and DNA damaging agents.
2023-03-11 | PXD034650 | Pride
Project description:Natural killer cells are innate lymphocytes that play a pivotal role in the immune surveillance and elimination of transformed or virally infected cells. Using a combined chemico-genetic approach, we have identified that BET bromodomains BRD2 and BRD4 are central regulators of NK cell responses. We show that both BRD2 and BRD4 play a key regulatory function in controlling NK cell specific inflammatory responses. However, knockdown of BRD2 but not BRD4 impairs NK cell cytolytic response, highlighting a redundant role for BRD4 in regulating NK cell killing. We further show that the prototypic monovalent BET inhibitor impairs in vitro NK cell mediated killing of cancer target cells, while the bivalent BET bromodomain AZD5153 does not. We ascribe these differences to the preferential affinity of JQ1(+) to BRD2, while AZD5153 has a higher affinity for BRD4. Our work suggests that inhibiting BET bromodomains may be an effective therapeutic strategy for controlling inflammatory function. Given that BRD2 but not BRD4 inhibition can impair NK cell mediated killing, our findings also have clinical significance in light of the ongoing clinical application of BET bromodomains in oncology.
2021-03-16 | GSE156423 | GEO
Project description:This study investigates the role of BET family member BRD4 in pancreatic islet organoid differentiation and endocrine cell development. Single-cell RNA sequencing was performed to characterize transcriptomic changes across three experimental systems: (1) human islet organoids following adenovirus-mediated BRD4 overexpression (B4OV) versus control; (2) pancreatic islets from α-cell-specific Brd4 knockout (αKO) mice versus control mice; and (3) stage 5 pancreatic endocrine progenitors following combined BRD4 activation and BRD2 suppression (B2sB4) versus control, after differentiation to stage 6. The dataset enables identification of BRD4-regulated gene expression programs and cellular heterogeneity during pancreatic endocrine differentiation.
2026-09-10 | GSE346272 | GEO